Phase 1 Cystic Fibrosis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
For healthy participants:
- Men and women between 18 and 55 years old who are in good general health
- People with a body mass index (a measure of body weight relative to height) between 18 and 32
- People whose lungs are working at 80% or more of the expected level, based on a breathing test
- People whose kidneys are filtering at a normal rate (90 mL/min or above)
- People whose blood tests and physical check-up results are normal, or only slightly outside the normal range in a way that is not medically concerning
For patients with a lung condition called non-cystic fibrosis bronchiectasis (NCFB) and a specific bacterial infection:
- Men and women between 18 and 80 years old with a confirmed diagnosis of bronchiectasis (a condition where the airways are permanently widened and damaged)
- People whose bronchiectasis has been confirmed by a CT scan
- People with a long-term infection caused by a bacterium called Pseudomonas aeruginosa, shown by two or more positive test results in the past 12 months
- People whose sputum (mucus coughed up from the lungs) tests positive for Pseudomonas aeruginosa at a certain level at the screening stage
- People whose lungs are working at 50% or more of the expected level after using a breathing-opening medication
Who may not be able to join:
For healthy participants:
- People with a significant medical history of illness or health conditions
- People who have had an acute (sudden) illness in the 4 weeks before screening
- People who currently smoke or use nicotine products
- People with a history of alcohol or drug misuse in the past 12 months
For patients with NCFB and Pseudomonas aeruginosa infection:
- People whose primary lung condition is asthma, chronic obstructive pulmonary disease (COPD), or cystic fibrosis
- People who have needed intravenous (IV) antibiotics for more than two lung flare-ups in the past 12 months
- People who have taken antibiotics (other than a specific type called macrolides) in the 30 days before screening
- People who have had significant coughing up of blood that required medical treatment in the 30 days before screening
- People currently receiving treatment for a separate lung infection caused by certain bacteria (called nontuberculous mycobacteria) or a fungal infection
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 619-512-3538
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Incidence and severity of treatment-emergent adverse events (AEs); Number of participants with clinically significant abnormalities in lab parameters, vital signs, respiratory function, and ECG parameters graded by FDA Toxicity Grading Scale (for healthy participants) and DAIDS Toxicity Tables (for NCFB patients)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.